Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
142,701 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 NOVEMBER 2024 at 9.00 EET...
Orion Research Foundation grants EUR 1,109,000 for research in 2025 Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press release 22 November, 2024 at 9.00 EET Orion Research...
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET Orion and Alligator...
Orion Corporation: Managers’ transactions – Henrik Stenqvist ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET Orion Corporation: Managers’ transactions – Henrik Stenqvist...
Orion Group Interim Report January–September 2024 ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET Orion Group Interim Report January–September 2024 Net sales totalled EUR...
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION24 OCTOBER 2024 at...
Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 ORION CORPORATION PRESS RELEASE 15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for...
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration...
Orion’s near-term climate targets approved by the Science Based Targets initiative ORION CORPORATIONPRESS RELEASE30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion’s near-term climate targets approved by...
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster ORION CORPORATION INVESTOR...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
